Gut Bacteria Molecule Reprograms Immune Checkpoints in Leukemia, Study Finds

If you've ever wondered whether the community of bacteria in your gut could have anything to do with how a cancer diagnosis unfolds in your bloodstream, a new blood cancer study suggests the answer may be yes, and the mechanism runs through the same short-chain fatty acids that come up whenever gut health is discussed. Researchers in Poland linked declining gut and mouth bacterial byproducts to the progression of chronic lymphocytic leukemia (CLL), the most common form of adult leukemia in Western countries, then showed in the lab that one of those byproducts can directly reprogram the immune "off switches" that let cancer cells hide from the immune system. It is early, cell-culture-stage evidence, not a treatment, but it adds CLL to the growing list of diseases where gut chemistry and immune checkpoint biology appear to be talking to each other.

Key takeaways:

• In 81 newly diagnosed CLL patients versus 21 healthy volunteers, the predicted capacity of gut and mouth bacteria to produce short-chain fatty acids (SCFAs) declined as leukemia stage advanced.
• In lab experiments on immune cells from 18 CLL patients, the SCFA sodium butyrate raised PD-1 and lowered TIGIT, two "checkpoint" proteins that cancer cells can exploit to evade the immune system.
• The microbiome findings are computational predictions, not directly measured metabolites, and the butyrate effects were shown only in isolated cells in a dish, not inside living patients.
• No conflicts of interest were reported, and the study does not support using butyrate or probiotic supplements as a treatment.

Gut and Mouth SCFA Pathways Decline as CLL Advances

Researchers found that the predicted capacity of gut and mouth bacteria to produce short-chain fatty acids (SCFAs, small molecules like butyrate, acetate, and propionate that bacteria make by fermenting fiber) drops as chronic lymphocytic leukemia (CLL) advances. In a study published in the British Journal of Haematology, a team led by Monika Szelest and colleagues at the Medical University of Lublin sequenced 16S ribosomal RNA, a gene fragment used to identify which bacteria are present in a sample, from stool and oral swabs, then used a computational tool called PICRUSt2 to estimate which metabolic pathways those bacterial communities were likely capable of running. In stool samples, 50 of 61 predicted metabolic pathway categories differed significantly between healthy volunteers and CLL patients grouped by Binet stage (the standard three-tier staging system, A through C, used to track how far CLL has progressed); in oral samples, 53 of 61 did. Pathways tied to producing SCFAs, breaking down carbohydrates, and building fatty acids were all lower in patients with more advanced disease (Binet stage B or C) than in healthy volunteers or patients at the earliest stage.

What This Means for Leukemia and Immune-Health Readers

This matters for a specific, if less commonly discussed, corner of gut-health interest: cancers of the immune system itself. CLL already carries an increased risk of infections because the disease blunts immune function, so anything that further dampens or activates immune cells is clinically relevant. The checkpoint proteins at the center of this study, PD-1 (programmed cell death protein 1) and TIGIT (T cell immunoreceptor with Ig and ITIM domains), are "off switches" that immune cells carry to avoid attacking healthy tissue, and cancers including CLL are known to exploit these switches to blunt the T cells that would otherwise attack them. That is also why immune checkpoint inhibitor drugs, which block PD-1 and related proteins to release the brakes on the immune system, have transformed treatment for several other cancers. If gut bacteria genuinely influence how active these checkpoints are, it opens a new, still-unproven avenue for understanding why some CLL patients' immune systems behave differently than others.

How the Study Tested 81 CLL Patients and an Ex Vivo Butyrate Experiment

The study compared oral and stool samples from 81 newly diagnosed CLL patients and 21 age-matched healthy volunteers recruited in Poland, with people on recent antibiotics or with recent gastrointestinal symptoms excluded from either group (oral samples: 86 total, 69 CLL and 17 healthy; stool samples: 96 total, 75 CLL and 21 healthy). After the sequencing-based metabolic pathway predictions, the researchers ran a second experiment to test whether those predicted changes did anything to immune cells: they isolated peripheral blood mononuclear cells (PBMCs, a mix of white blood cells that includes T cells) from 18 CLL patients, a genetically narrower subgroup chosen to reduce variability (patients with unmutated IGHV who lacked TP53 mutations and the 17p chromosomal deletion), and treated the cells for 48 hours with sodium butyrate. They then used flow cytometry, a technique that tags cells with fluorescent markers to measure which proteins sit on their surface, to track PD-1 and TIGIT levels before and after treatment.

What This Could Mean for Someone Managing Gut or Immune Health

For a CLL patient or their family, the honest read is that this is not a treatment, and butyrate supplements are not a substitute for oncology care. The experiment used purified sodium butyrate, in a lab dish, on immune cells removed from the body, and the effect it produced was mixed rather than uniformly protective: butyrate raised PD-1 expression on CD8+ T cells (p = 0.0182), the killer T cells most responsible for directly destroying cancerous or infected cells, while significantly lowering TIGIT on those same cells (p < 0.0001), on CD4+ "helper" T cells, and on the leukemic CD5+CD19+ B cells themselves (p = 0.011). In the leukemic B cells, butyrate lowered TIGIT but showed only a non-significant trend toward higher PD-1/TIGIT co-expression (p = 0.064). Because PD-1 and TIGIT can each suppress or, in some contexts, support immune activity depending on which cells carry them, the researchers describe this as evidence that gut-derived butyrate can modulate immune checkpoint biology in CLL, not proof that it improves outcomes. For readers without CLL, the broader takeaway is that the SCFAs your gut bacteria produce from dietary fiber appear to be biologically active well beyond the digestive tract, including on immune checkpoint pathways relevant to cancer biology; that is not a case for self-treating with butyrate or other SCFA supplements, which remain unproven for this purpose.

What the Study Doesn't Yet Prove About Butyrate or the Microbiome

The authors are explicit about several gaps. First, PICRUSt2 estimates what a bacterial community is metabolically capable of doing based on its genetic makeup; it does not directly measure SCFA levels in the gut or mouth, so the reduced-SCFA-pathway finding is a prediction, not a chemical measurement, and the team did not run metabolomics to confirm it. Second, the patient and volunteer samples were collected at a single point in time, so the study cannot say whether declining gut bacterial function drives CLL progression, results from it, or both. Third, the butyrate experiment was performed ex vivo, on cells taken out of the body, in that genetically narrower patient subgroup, so it demonstrates that butyrate can alter immune checkpoint expression in a dish, not that it does so, or changes disease course, inside a living patient. The study reports no conflicts of interest and was funded by Poland's National Science Centre and the Medical University of Lublin.

Next Steps: Metabolomics and Larger Butyrate Trials

The research team's own earlier work already linked gut bacterial imbalance to CLL outcomes, and a separate study by Faitova and colleagues found that reduced gut microbiome diversity tracks with more aggressive CLL in both patients and a mouse model of the disease. Building on that broader picture, the authors say the logical next step is pairing sequencing-based predictions with actual metabolomic measurement of SCFAs in blood and stool, alongside longitudinal sampling that tracks the same patients over time rather than comparing a snapshot of different people. They also note it remains to be tested whether butyrate's checkpoint effects hold up across CLL's genetic subtypes, including IGHV-mutated disease, which was excluded from this round of experiments. No clinical trial of butyrate or SCFA supplementation in CLL patients is described in this paper.

Common Questions About This Study

Does this mean probiotics or butyrate supplements can help treat leukemia? No. The study tested purified sodium butyrate on immune cells in a lab dish, not as an oral supplement in patients, and the researchers describe the checkpoint changes as proof-of-concept evidence that gut chemistry can influence immune signaling, not a treatment recommendation.

What are PD-1 and TIGIT, in plain terms? They are checkpoint proteins that immune cells display to keep from overreacting; cancers, including CLL, can exploit these same proteins to blunt the T cells that would otherwise attack the tumor, which is why checkpoint-blocking drugs already treat other cancers.

Is chronic lymphocytic leukemia caused by gut bacteria? The study does not show that. It shows an association between declining SCFA-related bacterial pathways and more advanced CLL, and shows that a gut-derived compound can alter immune checkpoint expression in isolated cells; it does not establish that microbiome changes cause the leukemia to progress.

Who ran the study and where? Researchers led by Monika Szelest at Poland's Medical University of Lublin, working with colleagues at the Medical University of Lodz and Wroclaw Medical University, collected the stool and oral samples and ran the butyrate experiments.

References

1. Monika Szelest, Joanna Zaleska, Michał Kiełbus, et al. (2026). Predicted microbiome‐associated metabolic pathways are linked to immune checkpoint modulation in chronic lymphocytic leukaemia. British Journal of Haematology. https://doi.org/10.1111/bjh.70797
2. Elizabeth R. Mann, Ying Ka Lam, Holm H. Uhlig (2024). Short-chain fatty acids: linking diet, the microbiome and immunity. Nature Reviews Immunology. https://doi.org/10.1038/s41577-024-01014-8